Use of epidermal growth factor receptor/Kirsten rat sarcoma 2 viral oncogene homolog mutation testing to define clonal relationships among multiple lung adenocarcinomas: comparison with clinical guidelines.

BACKGROUND The incidence of multiple lung adenocarcinomas is rising, making it difficult to determine the stage and assign treatment in an increasing number of patients following surgery. Clinical guidelines have been developed to distinguish independent non-small cell lung cancers from metastases, that is, criteria developed by Martini and Melamed and the American College of Chest Physicians (ACCP). However, these guidelines can be difficult to apply and may give conflicting results. Here, we report on seven patients in whom epidermal growth factor receptor (EGFR) and Kirsten-rat sarcoma 2 viral oncogene homolog (KRAS) tumor mutation status was used to determine clonal relationships among multiple lung lesions. METHODS We identified seven patients whose paired lung adenocarcinomas were found to harbor distinct EGFR or KRAS mutations. We assessed these patients' disease status using established clinical guidelines. We also explored the use of comprehensive histologic subtyping (CHS) of tumor sections to distinguish multiple primaries. RESULTS According to the Martini-Melamed criteria, six of the seven patients had multiple primary lung tumors. By ACCP criteria, three patients had multiple primaries, and three patients had metastases. Classification of the seventh patient by ACCP criteria was indeterminate. Mutational testing suggested that all paired tumors were multiple primary adenocarcinomas, which was consistent with results from CHS. CONCLUSIONS Assuming that independent tumor clones harbor distinct mutations, these seven cases highlight discrepancies between the existing clinical criteria used to distinguish independent tumor foci from metastases. EGFR/KRAS mutation testing of multiple lung adenocarcinomas can assist in differentiating multiple primary lung adenocarcinomas from metastatic lesions. Use of CHS in this setting should also be further explored.

[1]  J. Benfield,et al.  Clonal Origin of Multiple Lung Cancers: K‐ras and p53 Mutations Determined by Nonradioisotopic Single‐strand Conformation Polymorphism Analysis , 1997, Diagnostic molecular pathology : the American journal of surgical pathology, part B.

[2]  T. Nagayasu,et al.  Different epidermal growth factor receptor gene mutations in a patient with 2 synchronous lung cancers. , 2007, Clinical lung cancer.

[3]  Julio Astudillo,et al.  Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. , 2006, The Lancet. Oncology.

[4]  C. Mountain,et al.  Revisions in the International System for Staging Lung Cancer. , 1997, Chest.

[5]  M. Ladanyi,et al.  Rapid polymerase chain reaction-based detection of epidermal growth factor receptor gene mutations in lung adenocarcinomas. , 2005, The Journal of molecular diagnostics : JMD.

[6]  V. Seshan,et al.  Prognostic and Therapeutic Implications of EGFR and KRAS Mutations in Resected Lung Adenocarcinoma , 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[7]  Yih-Leong Chang,et al.  Clonality and Prognostic Implications of p53 and Epidermal Growth Factor Receptor Somatic Aberrations in Multiple Primary Lung Cancers , 2007, Clinical Cancer Research.

[8]  R. Munden,et al.  Management of small (3-5-mm) pulmonary nodules at chest CT: global survey of thoracic radiologists. , 2008, Radiology.

[9]  H. Varmus,et al.  KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib , 2005, PLoS medicine.

[10]  G. Giaccone,et al.  Genetic Heterogeneity in Patients with Multiple Neoplastic Lung Lesions: A Report of Three Cases , 2007, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[11]  Synchronous multiple primary lung cancers with different response to gefitinib. , 2006, Lung cancer.

[12]  G. Snow,et al.  Second primary tumors and field cancerization in oral and oropharyngeal cancer: Molecular techniques provide new insights and definitions , 2002 .

[13]  W. Gerald,et al.  Lung Adenocarcinoma: Modification of the 2004 WHO Mixed Subtype to Include the Major Histologic Subtype Suggests Correlations Between Papillary and Micropapillary Adenocarcinoma Subtypes, EGFR Mutations and Gene Expression Analysis , 2008, The American journal of surgical pathology.

[14]  Brian H. Dunford-Shore,et al.  Somatic mutations affect key pathways in lung adenocarcinoma , 2008, Nature.

[15]  E. Mark,et al.  Carcinogen exposure, p53 alteration, and K‐ras mutation in synchronous multiple primary lung carcinoma , 1999, Cancer.